TCV-309 chloride

Research use only, not for human use.

A highly potent and selective platelet activating factor (PAF) antagonist; inhibits PAF-induced aggregation of rabbit and human platelets with IC50s of 33 nM and 55 nM respectively.

A highly potent and selective platelet activating factor (PAF) antagonist; inhibits PAF-induced aggregation of rabbit and human platelets with IC50s of 33 nM and 55 nM respectively; potently protects mice from death induced by PAF and due to anaphylactic shock with ED50 of 2.1 and 2.6 ug/kg (i.v.), respectively; also reverses PAF-induced hypotension and endotoxin-induced hypotension in rats.Coagulation DisorderPhase 2 Discontinued.

——

In rats, TCV-309 selectively inhibits the PAF-induced hypotension, hemoconcentration and death with ED50 values of 2.7, 6.4 and 1.7 micrograms/kg (i.v.), respectively. TCV-309 most potently protects mice from death induced by PAF and due to anaphylactic shock with ED50 values of 2.1 and 2.6 micrograms/kg (i.v.), respectively. TCV-309 chloride also reversed PAF-induced hypotension and endotoxin-induced hypotension in rats with ED50 values of 3.3 and 1.2 micrograms/kg (i.v.), respectively.

TCV309 chloride | TCV 309 chloride

Others

Other Targets

Other Targets

Cardiovascular Disease

Coagulation Disorder

121494-09-5

629.9724

C30H34BrClN4O4

>98% (HPLC)

DMSO: ≥ 6.3 mg/mL

CCC[N+]1=CC(=CC(=C1)Br)C(=O)N(CCC(=O)NCCOC(=O)N2CCC3=CC=CC=C3C2)C4=CC=CC=C4.[Cl-]

Pyridinium, 3-bromo-5-[[[3-[[2-[[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]oxy]ethyl]amino]-3-oxopropyl]phenylamino]carbonyl]-1-propyl-, chloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years